VANCOUVER, Jan. 22 /CNW/ - Genome BC is pleased to invite media to attend
the public launch of a genomics research project that seeks to understand and
prevent adverse drug reactions in children by developing genomic tools to
Adverse drug reactions are reported to be the fifth leading cause of
death in Canada and cost the Canadian Healthcare system over 13 billion
dollars per year.
This one of a kind research project, co-led by internationally-renowned
researchers Dr. Michael Hayden and Dr. Bruce Carleton, aims to use patient's
genetic information to predict adverse reactions to common drugs and develop a
tool that will allow doctors to tailor medications to their specific needs,
thereby reducing the number of adverse drug reactions.
What: The public launch of research project "Genotype Specific
Approaches to Therapy in Childhood: The Canadian Pharmacogenomics
Network for Drug Safety"
When: Friday January 23rd at 11:00 a.m. (a light lunch will be provided)
Where: The Chan Centre for Family Health Education (Auditorium) at the
Child & Family Research Institute - 950 West 28th Avenue,
About Genome BC:
Genome British Columbia is a research organization that invests in and
manages large-scale genomics and proteomics research projects and science and
technology platforms focused on areas of strategic importance such as human
health, forestry, fisheries, ethics, agriculture, and the environment. By
working collaboratively with all levels of government, universities and
industry, Genome BC is the catalyst for a vibrant, genomics-driven life
sciences cluster with far reaching social and economic benefits for the
Province and Canada.
For further information:
For further information: visit www.genomebc.ca; Media Contacts: Rachael
Froese Zamperini, Communications Consultant, Genome BC, (604) 612-6345; Julia
White, Communications Officer, Genome BC, (604) 637-4378